FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108293816> ?p ?o ?g. }

• W2108293816 endingPage "614" @default.
• W2108293816 startingPage "603" @default.
• W2108293816 abstract "To assess the antitumour activity and safety profile of irinotecan and its pharmacokinetic interactions with anticonvulsants in patients with glioblastoma multiforme.This multicentre phase II and pharmacokinetic study investigated the effects of irinotecan 350 mg/m(2) given as a 90-min infusion every 3 weeks either prior to (group A) or after relapse following radiotherapy (group B) in chemotherapy-naïve patients with glioblastoma. Preferred concomitant medication for seizure prevention was valproic acid. Pharmacokinetic analysis of irinotecan and its main metabolites (SN-38, SN-38-G, APC and NPC) was performed during cycle 1. An independent panel of experts reviewed the activity data.Fifty-two patients (25 patients in group A and 27 patients in group B) received a total of 191 cycles of irinotecan. Forty-six patients (22 patients in group A and 24 patients in group B) were evaluable and externally reviewed for activity. According to external review, one partial response (group B), seven minor responses (three in group A and four in group B), 12 disease stabilisations (seven in group A and five in group B) were observed. This resulted in an overall response rate of only 2.2% (95% confidence interval 0.2% to 6.5%). The median time to tumour progression was 9 weeks in group A and 14.4 weeks in group B. Six-month progression-free survival rates were 26% in group A and 43% in group B. Grade 3-4 toxicities (percentage of patients in groups A and B) consisted of neutropenia (12.5% and 25.9%), diarrhoea (8.3% and 7.4%), asthenia (12.5% and 7.4%) and vomiting (0% and 7.4%). The clearance of irinotecan was 12.4 and 14.4 l/h/m(2) in two patients who received no anticonvulsant. In patients receiving valproic acid, the clearance of irinotecan was 17.2 +/- 4.4 l/h/m(2).Irinotecan given at the dose of 350 mg/m(2) every 3 weeks has limited clinical activity as a single agent in patients with newly diagnosed and recurrent glioblastoma after radiotherapy. The toxicity profile and plasma disposition of irinotecan and SN-38 were not strongly influenced by anticonvulsant valproic acid therapy. Although the response rate of irinotecan as a single agent was limited, it remains an attractive drug for combination studies in patients with glioblastoma." @default.
• W2108293816 created "2016-06-24" @default.
• W2108293816 creator A5001307415 @default.
• W2108293816 creator A5002864173 @default.
• W2108293816 creator A5003526236 @default.
• W2108293816 creator A5005004507 @default.
• W2108293816 creator A5013952219 @default.
• W2108293816 creator A5041492973 @default.
• W2108293816 creator A5043515892 @default.
• W2108293816 creator A5055791669 @default.
• W2108293816 creator A5067202962 @default.
• W2108293816 creator A5075460094 @default.
• W2108293816 creator A5082689339 @default.
• W2108293816 creator A5086083902 @default.
• W2108293816 date "2003-04-01" @default.
• W2108293816 modified "2023-10-18" @default.
• W2108293816 title "Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma" @default.
• W2108293816 cites W106814647 @default.
• W2108293816 cites W1585209741 @default.
• W2108293816 cites W1774923611 @default.
• W2108293816 cites W1898063915 @default.
• W2108293816 cites W1927999720 @default.
• W2108293816 cites W1959628099 @default.
• W2108293816 cites W1973027090 @default.
• W2108293816 cites W1975284341 @default.
• W2108293816 cites W1976935937 @default.
• W2108293816 cites W1992948093 @default.
• W2108293816 cites W1993808515 @default.
• W2108293816 cites W2001842691 @default.
• W2108293816 cites W2006774085 @default.
• W2108293816 cites W2006824814 @default.
• W2108293816 cites W2011909208 @default.
• W2108293816 cites W2014851842 @default.
• W2108293816 cites W2018500298 @default.
• W2108293816 cites W2019867999 @default.
• W2108293816 cites W2036560693 @default.
• W2108293816 cites W2044952801 @default.
• W2108293816 cites W2059184955 @default.
• W2108293816 cites W2061554178 @default.
• W2108293816 cites W2080229627 @default.
• W2108293816 cites W2088925558 @default.
• W2108293816 cites W2096122707 @default.
• W2108293816 cites W2098822886 @default.
• W2108293816 cites W2110718863 @default.
• W2108293816 cites W2113157575 @default.
• W2108293816 cites W2160740155 @default.
• W2108293816 cites W2246769930 @default.
• W2108293816 cites W2264385870 @default.
• W2108293816 cites W2329791077 @default.
• W2108293816 cites W3191411997 @default.
• W2108293816 doi "https://doi.org/10.1093/annonc/mdg159" @default.
• W2108293816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12649109" @default.
• W2108293816 hasPublicationYear "2003" @default.
• W2108293816 type Work @default.
• W2108293816 sameAs 2108293816 @default.
• W2108293816 citedByCount "75" @default.
• W2108293816 countsByYear W21082938162012 @default.
• W2108293816 countsByYear W21082938162013 @default.
• W2108293816 countsByYear W21082938162014 @default.
• W2108293816 countsByYear W21082938162015 @default.
• W2108293816 countsByYear W21082938162016 @default.
• W2108293816 countsByYear W21082938162017 @default.
• W2108293816 countsByYear W21082938162018 @default.
• W2108293816 countsByYear W21082938162020 @default.
• W2108293816 countsByYear W21082938162022 @default.
• W2108293816 crossrefType "journal-article" @default.
• W2108293816 hasAuthorship W2108293816A5001307415 @default.
• W2108293816 hasAuthorship W2108293816A5002864173 @default.
• W2108293816 hasAuthorship W2108293816A5003526236 @default.
• W2108293816 hasAuthorship W2108293816A5005004507 @default.
• W2108293816 hasAuthorship W2108293816A5013952219 @default.
• W2108293816 hasAuthorship W2108293816A5041492973 @default.
• W2108293816 hasAuthorship W2108293816A5043515892 @default.
• W2108293816 hasAuthorship W2108293816A5055791669 @default.
• W2108293816 hasAuthorship W2108293816A5067202962 @default.
• W2108293816 hasAuthorship W2108293816A5075460094 @default.
• W2108293816 hasAuthorship W2108293816A5082689339 @default.
• W2108293816 hasAuthorship W2108293816A5086083902 @default.
• W2108293816 hasBestOaLocation W21082938161 @default.
• W2108293816 hasConcept C112705442 @default.
• W2108293816 hasConcept C121608353 @default.
• W2108293816 hasConcept C126322002 @default.
• W2108293816 hasConcept C141071460 @default.
• W2108293816 hasConcept C143998085 @default.
• W2108293816 hasConcept C2776694085 @default.
• W2108293816 hasConcept C2777063308 @default.
• W2108293816 hasConcept C2777785397 @default.
• W2108293816 hasConcept C2779384505 @default.
• W2108293816 hasConcept C2780259306 @default.
• W2108293816 hasConcept C44249647 @default.
• W2108293816 hasConcept C526805850 @default.
• W2108293816 hasConcept C71924100 @default.
• W2108293816 hasConcept C90924648 @default.
• W2108293816 hasConceptScore W2108293816C112705442 @default.
• W2108293816 hasConceptScore W2108293816C121608353 @default.
• W2108293816 hasConceptScore W2108293816C126322002 @default.
• W2108293816 hasConceptScore W2108293816C141071460 @default.
• W2108293816 hasConceptScore W2108293816C143998085 @default.

• next